Viral Immunotherapy in Relapsed/Refractory Multiple Myeloma
Status:
Active, not recruiting
Trial end date:
2021-10-01
Target enrollment:
Participant gender:
Summary
This study will recruit patients currently receiving either lenalidomide or pomalidomide
whose disease is relapsing. This is a dose escalation study and the aim is to determine the
maximum tolerated dose (MTD) of REOLYSIN® that can be given in combination with lenalidomide
or pomalidomide. The study will also investigate the safety, side effects and effectiveness
of this treatment combination. Pomalidomide and lenalidomide will be evaluated separately as
two separate groups.